Additional file 1: Figure S1. of Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials

Quality assessment. (A) Risk of bias summary. (B) Risk of bias graph. (PPTX 76 kb

Additional file 2: Figure S2. of Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials

Effect of PDE5i on BP and HR. Forest plot of the pooled weighted mean differences of (A) SBP (mmHg), (B) DBP (mmHg), (C) MAP (mmHg), and (D) HR (beat per minute). Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate. Figure S3. Effect of PDE5i on cardiac performance. Forest plot of the pooled weighted mean differences of (A) cardiac index (L/min/m2), and (B) cardiac output (L/min). (TIF 5850 kb

Additional file 3: Figure S4. of Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials

Influence analysis for the RCTs of HFpEF. Sensitivity analysis was performed to assess the potential influence of each RCT to the effect size of the RCTs of HFpEF. Pooled effects of PDE5i when each RCT was omitted were shown for (A) LVEF (%), (B) mPAP (mmHg), (C) PASP (mmHg), and (D) PVR (dyn¡sec/cm5). The omission of the study by Guazzi M et al. [12] significantly changed the pooled effect size of PDE5i, suggesting that there was a substantial influence from the study by Guazzi M et al. on the overall outcome measures. Abbreviations: RCT, randomized controlled trial; HFpEF, heart failure with preserved ejection fraction; PDE5i, phosphodiesterase type 5 inhibitor; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PVR, pulmonary vascular resistance. (PPTX 588 kb

Additional file 2: of Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial

Supplementary methods for details of imaging protocols. (DOCX 26 kb

Additional file 1: of Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial

SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOCX 48 kb

Baseline characteristics of total study population.

<p>Data are mean±SD, median (IQR; Q1–Q3) or number (%).</p><p>*Chronic kidney disease was defined as estimated glomerular filtration rate (GFR) <60 mL/min/1.73m².</p><p>^†Calculations of the laboratory tests and coronary artery calcium score were performed for those with available data of each component.</p><p>^‡A composite of all-cause mortality and late coronary revascularization (>90 days after CCTA), including percutaneous coronary intervention and coronary artery bypass graft operation.</p><p>Abbreviations: COPD, chronic obstructive pulmonary disease; ACEi, angiogensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; GFR, glomerular filtration rate; CACS, coronary artery calcium score; CCTA, coronary computed tomography angiography.</p><p>Baseline characteristics of total study population.</p

Risk-adjusted survival curves of aspirin users versus non-users.

<p><b>A,</b> All-cause mortality-free survival by aspirin therapy in patients with non-obstructive coronary artery disease (1–49% stenosis). <b>B,</b> Composite endpoint (all-cause mortality or late coronary revascularization)-free survival by aspirin therapy. Survival analyses were performed using age, gender, comorbidities and concurrent medications as covariates.</p

Cox proportional hazard model for all-cause mortality.

<p>Variables in the model are as follows: age, gender, diabetes, hypertension, and the use of statin, aspirin, clopidogrel, beta blocker, CCB, ACEi, and ARB.</p><p>Abbreviations: ACEi, angiogensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio.</p><p>Cox proportional hazard model for all-cause mortality.</p

Multivariable Cox proportional hazard model for the composite endpoint^*.

<p>* Composite endpoint: a composite of all-cause mortality and late coronary revascularization.</p><p>Abbreviations: ACEi, angiogensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio.</p><p>Multivariable Cox proportional hazard model for the composite endpoint^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0129584#t003fn001" target="_blank">*</a>}.</p

Association between post-CCTA aspirin therapy and the composite endpoint in subgroups.

<p>Risk-adjusted effects of aspirin therapy on the composite of mortality and late coronary revascularization (>90 days after CCTA) were analyzed in subgroups divided by age of 65 years, gender, presence of diabetes mellitus, presence of hypertension, and the results of CACS, LDL-C, hsCRP and GFR.</p